Xencor, Inc. (NASDAQ:XNCR) Major Shareholder John S. Stafford III Acquires 24,653 Shares

Xencor, Inc. (NASDAQ:XNCR) major shareholder John S. Stafford III acquired 24,653 shares of the stock in a transaction dated Wednesday, October 25th. The shares were bought at an average price of $20.01 per share, with a total value of $493,306.53. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Shares of Xencor, Inc. (NASDAQ XNCR) opened at $21.03 on Friday. Xencor, Inc. has a 1-year low of $18.55 and a 1-year high of $29.38.

WARNING: This piece of content was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece of content on another website, it was stolen and reposted in violation of United States and international copyright & trademark laws. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2017/11/12/john-s-stafford-iii-buys-24653-shares-of-xencor-inc-xncr-stock.html.

A number of brokerages have recently issued reports on XNCR. Zacks Investment Research downgraded Xencor from a “hold” rating to a “sell” rating in a research report on Saturday. Canaccord Genuity restated a “buy” rating and set a $36.00 price objective on shares of Xencor in a research report on Tuesday, August 8th. ValuEngine downgraded Xencor from a “hold” rating to a “sell” rating in a research report on Monday, October 23rd. Finally, BidaskClub downgraded Xencor from a “hold” rating to a “sell” rating in a research report on Monday, August 14th. Three investment analysts have rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $28.67.

A number of hedge funds have recently modified their holdings of the business. Alps Advisors Inc. increased its holdings in Xencor by 0.3% in the second quarter. Alps Advisors Inc. now owns 20,102 shares of the biopharmaceutical company’s stock worth $424,000 after purchasing an additional 52 shares in the last quarter. Falcon Point Capital LLC increased its holdings in Xencor by 0.5% in the second quarter. Falcon Point Capital LLC now owns 29,082 shares of the biopharmaceutical company’s stock worth $614,000 after purchasing an additional 156 shares in the last quarter. Parametric Portfolio Associates LLC increased its holdings in Xencor by 0.6% in the first quarter. Parametric Portfolio Associates LLC now owns 36,253 shares of the biopharmaceutical company’s stock worth $867,000 after purchasing an additional 209 shares in the last quarter. Legal & General Group Plc increased its holdings in Xencor by 4.5% in the second quarter. Legal & General Group Plc now owns 8,978 shares of the biopharmaceutical company’s stock worth $189,000 after purchasing an additional 385 shares in the last quarter. Finally, Cornerstone Capital Management Holdings LLC. increased its holdings in Xencor by 2.3% in the second quarter. Cornerstone Capital Management Holdings LLC. now owns 23,321 shares of the biopharmaceutical company’s stock worth $492,000 after purchasing an additional 521 shares in the last quarter. Institutional investors and hedge funds own 76.81% of the company’s stock.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.

Insider Buying and Selling by Quarter for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply